PDB41 Health care resource utilization and costs associated with various stages of chronic kidney disease among type 2 diabetes mellitus patients  by Chuang, C.C. et al.
A244  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
PPPM), the propensity score method was less robust against unobserved confound-
ing factors than the doubly robust estimation method.
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Objectives: To compare health care costs between type 2 diabetes mellitus 
(T2DM) patients newly initiating exenatide once weekly (exenatide QW), exena-
tide twice daily (exenatide), or liraglutide (LIRA). MethOds: This administra-
tive claims-based retrospective cohort study included patients if they had T2DM, 
were GLP-1RA-naïve, initiated a GLP-1RA between 2/1/2012-6/30/2012 (initiation 
date= index), were aged ≥ 18 years, and had continuous enrollment for 12 months 
before (baseline) to 6 months after index (follow-up). Outcomes included health 
care costs (Total/Diabetes-related/GLP-1RAs) and hospitalizations (Total/Diabetes-
related). Diabetes-related outcomes included those associated with antidiabetes 
medications and medical claims coded with T2DM ICD-9-CM codes. Outcomes were 
compared between index GLP-1RAs using multivariable generalized linear models. 
Pre-specified sensitivity analyses were performed stratifying by LIRA 1.2mg and 
LIRA 1.8mg and among patients with ≥ 60 days’ supply of their index GLP-1RA within 
≤ 67 days after index (initial adherers). Results: The study sample included 1,610 
exenatide QW, 2,690 exenatide, and 6,499 LIRA patients. In multivariable-adjusted 
models, health care costs varied widely across GLP-1RAs and analyses, with exena-
tide generally being associated with the lowest adjusted health care costs (cost 
ratios vs. exenatide QW ranging from 0.762 [p< 0.001] for GLP-1RA costs to 0.908 
[p< 0.001] for Total costs among initial adherers). LIRA 1.8mg was generally associ-
ated with the highest adjusted health care costs (cost ratios vs. exenatide QW rang-
ing from 1.039 [p= 0.080] for Total costs to 1.157 [p< 0.001] for GLP-1RA costs among 
initial adherers). LIRA 1.2mg was generally associated with the highest adjusted 
odds of hospitalizations (odds ratios vs. exenatide QW ranging from 1.312 [p= 0.317] 
for diabetes-related hospitalizations to 1.528 [p< 0.036] for total hospitalizations 
among initial adherers). cOnclusiOns: Among patients newly initiating exenatide 
QW, exenatide, or LIRA, differences existed in health care costs and hospitalization 
in first 6 months of treatment. LIRA 1.8mg and 1.2mg were generally associated 
with the highest adjusted health care costs and odds of hospitalization, respectively.
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Objectives: To compare costs of two delivery systems (pen vs. vials/syringes) 
of recombinant human growth hormone (rGH) in Brazilian GH deficient 
patients. MethOds: A budgetary impact model was developed to calculate total 
costs based on product waste (difference between prescribed dose and actual deliv-
ered dose, based on dosing increments for pens [Pfizer Gocquick 16UI and 36UI – P16 
and P36, respectively] and a fixed-percent waste described in the literature for vials 
[Hormotrop 4UI and 12UI – V4 and V12, respectively]) and drug cost. Annual acquisi-
tion costs were calculated based upon total milligrams delivered, for pediatric and 
adult patients. Dose was 0,03mg/kg/day for children and 0,15mg/day for adults. It 
was considered both public and private payer perspectives. Results: For children, 
calculated waste was 2.56% and 7.69% for P16 and P36, respectively; for adults, it was 
0% for both versions. Waste for vials was fixed in 23% for all scenarios. From the pub-
lic payer perspective, total cost per treatment-year for children was BRL26,256.96, 
BRL25,396.38, BRL33,702.73 and BRL32,683.92 for P16, P36, V4 and V12, respectively 
and waste cost was BRL2,019.77, BRL1,953.57, BRL7,751,63 and BRL7,517.30; for 
adults, total cost per treatment-year was BRL3,750.99, BRL3,628.05, BRL5,185,04 
and BRL5,028.30 for P16, P36, V4 and V12, respectively and waste cost was BRL0.00, 
BRL0.00, BRL1,192.56 and BRL1,156,51. From the private payer perspective, total cost 
per treatment-year was, respectively, BRL32,027.03, BRL32,526.11, BRL43,164.19 and 
BRL41,858.67 for P16, P36, V4 and V12, and waste cost was BRL2,586.80, BRL2,502.01, 
BRL9,927.76 and BRL9,627.49 in children; for adults, total cost per treatment-
year was BRL4,804.05, BRL4,646.59, BRL6,640.64 and BRL6,439.79 for P16, P36, 
V4 and V12, respectively and waste cost was BRL0.00, BRL0.00, BRL1,527.35 and 
BRL1,481.15. cOnclusiOns: For pediatric and adult patients, rGH administration 
through pens was less costly, and had less waste than vials/syringes, from both 
public and private perspectives. P36 use was the best option in this analysis.
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Objectives: Uncontrolled type 2 diabetes mellitus (T2DM) increases the risk of 
chronic kidney disease (CKD). This study examined the health care resource utili-
zation (HRU) and costs among T2DM patients with varying degrees of CKD using 
electronic health records. MethOds: This retrospective study was conducted using 
electronic health records from US integrated delivery networks from 2008 to 2012. 
Adult T2DM patients (first T2DM diagnosis denotes index date) with continuous 
medical activity during the 6-month pre- and 12-month post-index period and lab 
values for CKD classification were selected. CKD stages were assessed using the 
estimated glomerular filtration rate and urine albumin to creatinine ratio. HRU/costs 
by CKD stage (Stages 1, 2, 3A, 3B, and 4) were captured from the 12-month follow-up 
data and compared to T2DM patients without CKD (no CKD). Unit cost approach was 
applied to derive medical encounter costs. Multivariate regression analyses were 
Objectives: Patients who do not incorporate diet modifications in their therapy 
regimen may create an undesirable escalation in blood glucose level leading to 
hyperglycemia and chronic complications. The objective of this study is to investi-
gate the prevalence of diabetic patients who incorporate diet modification in their 
therapy, and its association with health care utilization and expenditures for the 
U.S. civilian noninstitutionalized population. MethOds: Our study was conducted 
with a quasi-experimental design approach. Subjects included were patients who 
reported being diagnosed with diabetes and reported the treatment of diabetes 
with diet modification from the 2011 Medical Expenditure Panel Survey. A series of 
weighted inferential statistics were used to test the effect of diet modification on 
the variables associated with health care use and expenditures. All analyses were 
accomplished by taking into consideration MEPS sample adjustments using SAS 
9.3. Results: There were an estimated 21.8 million who have been diagnosed with 
diabetes in the US in 2011, of which, 4.6 million (21%) did not include diet modifica-
tion in their therapy. For total health care expenditures, those who did not include 
diet modification had more expenditure (M = $11,230, SE = 811.84) comparing with 
those who included diet modifications (M = $10,638, SE = 487.25), t (172) = 25.26, 
p< .0001. Moreover, total inpatient expenditure for those who did not include diet 
modification (M = $3,003, SE = 497.3) and patients who included diet modification 
(M = $2545.66, SE = 251.45), revealed a significant difference between the groups; t 
(172) = 12.33, p< .0001. cOnclusiOns: The study findings indicated that diabetic 
patients with diet modification had significant lower utilization and expenditures. 
Regulating diet is extremely important for people who have diabetes. It can be very 
effective in preventing or postponing the progression of diabetes, and subsequently 
managing the cost and utilization associated with it.
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Objectives: To determine cost savings related to growth hormone (GH) treatment 
and impact on height outcome when a data-driven approach is used, compared to 
conventional treatment approach based on experience, in pre-pubertal patients 
with growth hormone deficiency (GHD) and Turner syndrome (TS). MethOds: A 
model had been developed previously to study height outcome and total GH cost 
in the presence or absence of data-driven treatment decisions. The proportion of 
patients for whom height outcome could be improved or GH use could be reduced 
(i.e. for low compliance, or high or low responders) was estimated using a cohort 
from the Pfizer International Growth Database (KIGS). This model was adapted to 
Brazilian patients, for both private and public perspectives, resulting in 4 scenarios: 
(1) Genotropin 16UI private, (2) Genotropin 36UI private, (3) Genotropin 16UI public 
and (4) Genotropin 36UI public. Eligible patients were calculated by applying local 
prevalence rates to infant population (n= 13,686 GHD and 15,641 TS). The analysis 
used a 4-year time horizon. Effects were defined as height outcome after 4 years 
and total treatment cost. Results: The analysis estimated that the data-driven 
approach could reduce total cost of GH therapy by 7.1% over 4 years for the treat-
ment of Brazilian patients with GHD and by 6.7% for patients with TS, representing 
a reduction of 7.0% for all subjects. Total costs for all scenarios, when the conven-
tional approach is used were: (1) BRL3,572,931,540.80, (2) BRL3,455,666,095.35, (3) 
BRL2,789,533,217.78 and (4) BRL2,698,326,760.21; with the data-driven approach, total 
costs were: (1) BRL3,327,729,748.47, (2) BRL3,218,511,951.60, (3) BRL2,598,094,188.81 
and (4) BRL2,513,147,013.46. Despite the reduction in treatment costs, the average 
height remained unaffected. cOnclusiOns: In Brazil, the data-driven approach 
could be a useful tool to guide treatment decisions for children with GHD and TS. 
Total costs of GH treatment could be reduced, without having an impact on growth 
outcomes.
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Objectives: To compare the doubly robust estimation and propensity score meth-
ods in a diabetes-related comparative health economics study. MethOds: We used 
large US claims databases that covered 115 million patients between 2000 and 2011. 
Patients with type 2 diabetes with continuous health insurance were selected into 
the intensification cohort or non-intensification cohort depending on whether they 
intensified basal insulin with insulin aspart or remained on treatment with basal 
insulin without bolus insulin. The study measured the patients’ demographic and 
clinical characteristics, as well as their health care utilization and medical costs in 
a 6-month pre-baseline period and a 12-month post-baseline period. Doubly robust 
estimation and propensity score methods were used to examine the impact of inten-
sification on direct medical costs per patient per month (PPPM). Results: The study 
included 26,016 qualified patients with 2,860 in the intensification cohort and 23,156 
in the non-intensification cohort. Baseline characteristics were similar between 
the two cohorts (mean age= 58 years, percentage male= 52%). Both cohorts also had 
similar prevalence rates of diabetes-related conditions, and similar utilization and 
medical costs in the pre-baseline period. The propensity score method indicated 
that the intensification cohort spent $297.4 PPPM less in the post-baseline period 
than the non-intensification cohort (p< 0.05), while the doubly robust estimation 
method estimated a $399.0 PPPM cost reduction due to treatment intensification 
(p< 0.05). The doubly robust estimation method was able to control all confounding 
factors also controlled by the propensity score method, as well as additional con-
founding factors not controlled by the propensity score method. cOnclusiOns: 
Although both the propensity score and doubly robust estimation methods revealed 
cost savings due to treatment intensification with insulin aspart ($297.4 vs. $399.0 
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objectives. Adult patients with type 2 diabetes mellitus (T2DM) newly initiating 
treatment between January 1, 2010, and December 31, 2011, with either saxagliptin 
or sitagliptin were identified. A 1:1 propensity-matched sample of saxagliptin and 
sitagliptin patients was created to reduce any potential confounding. Propensity 
scores were generated based on demographic characteristics, comorbidities, disease 
severity and treatment patterns before the index date. Patients were required to 
have ≥ 6 months of continuous eligibility before (baseline period) and after (follow-
up period) treatment initiation. All outcomes were assessed based on an intent-to-
treat analysis in the 6-month follow-up period. Both overall and diabetes-specific 
charges were computed; breakdowns of medical and overall (medical plus phar-
macy) charges were compared. Appropriate univariate statistical tests were applied 
to the propensity-matched sample to examine differences in resource utilization 
outcomes. Results: A total of 8,438 and 23,155 patients initiated treatment with 
saxagliptin and sitagliptin, respectively. After matching, each cohort consisted of 
7,700 patients. Compared with sitagliptin, during the follow-up period, saxagliptin 
was associated with significantly lower (all p values ≤ 0.01) overall charges ($13,203 
± $28,391 vs. $14,258 ± $35,586), diabetes-related overall charges ($5,106 ± $12,129 vs. 
$5,402 ± $14,201), overall medical charges ($9,454 ± $27,616 vs. $10,502 ± $34,903), and 
diabetes-related medical charges ($3,389 ± $12,080 vs. $3,689 ± $14,161). Accordingly, 
saxagliptin was associated with a lower proportion of patients recording an inpa-
tient stay (6.6% vs. 8.1%; p= 0.001) or diabetes-related inpatient stay (4.6% vs. 5.4%; 
p= 0.025). cOnclusiOns: Patients initiating saxagliptin treatment reported lower 
charges and lower hospitalization rates (overall and diabetes-related) compared 
with patients initiating sitagliptin.
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Objectives: Wearable health monitoring devices have become increasingly avail-
able and allow for real-time tracking of clinical values. This research aims to assess 
the trends in continuous glucose monitor (CGM) uptake and to examine differences 
in costs and resource utilization following their initial use. MethOds: Adults aged 
18-64 with a diagnosis for diabetes (ICD-9-CM 250.xx) and continuous enrollment 
in commercial insurance were identified from the Truven Health MarketScan 
databases (2008-2012). An initial procedure code for CGM (CPT 95250) at least one 
year after the initial diagnosis and the lack of a previous claim for CGM identi-
fied eligible subjects within each year from 2009-2011; the date of the qualifying 
CGM claim served as the index date. Costs and utilization for pharmacy, inpatient, 
emergency department, specialty, laboratory, and primary care services were com-
pared between each annual cohort and between the year prior to and following the 
index date. Results: From 2009 to 2011, the number of initial patients using CGM 
declined, from 1,001 to 770 (p-value for trend < 0.001). The total average costs to treat 
these patients increased between 2009 and 2010 before declining in 2011, mostly due 
to dramatic changes in costs related to outpatient pharmacy and inpatient services. 
Compared to before the CGM was placed, mean annual costs for primary care visits 
and laboratory services tended to decrease while the average number of primary 
care visits consistently and significantly declined (all p< 0.05). However, noticeably 
higher mean costs related to outpatient pharmacy services were accrued following 
CGM use in both 2009 and 2010. cOnclusiOns: Devices such as CGM may benefit 
ongoing patient care by providing more regular insight to treatment progression 
and, in some cases, lead to more efficient care.
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Objectives: As novel treatments for type II diabetes enter the market, there is a 
need to assess their long-term clinical and economic outcomes compared to cur-
rent treatments. These comparisons can assist decision-makers in determining 
the appropriate place in therapy. Our objective was to review the existing phar-
macoeconomic literature evaluating the cost-effectiveness and overall costs of 
treatment associated with liraglutide in type II diabetes. MethOds: We identified 
English-language cost-effectiveness, cost-utility or cost analyses that compared 
liraglutide to one or more anti-diabetic agents via MEDLINE and EMBASE through 
March 1, 2013. Full text articles meeting the inclusion criteria were retrieved and 
information on the study design and results were abstracted. Costs were converted 
to 2012 US dollars in order to facilitate comparisons across studies. Results: A 
total of 3 cost comparison studies and 6 cost-utility studies were identified for 
inclusion. Across cost comparison studies, liraglutide treatment resulted in cost 
savings ranging from $1,075 to $1,298 (1.2 mg) and $1,162 to $2,147 (1.8 mg) over a 
10 year time horizon. Cost-utility analysis results reported base case ICERs ranging 
from $15,774 to $40,128/QALY for liraglutide 1.2 mg and $8,497 to $66,031/QALY 
for liraglutide 1.8 mg. Estimates were most sensitive to variations in time horizon 
and cardiovascular complication rates. Based on often cited cost-utility thresholds, 
liraglutide was determined to have a probability of being cost effective between 58% 
(liraglutide 1.8 mg vs. sitagliptin 100 mg) and 93% (liraglutide 1.2 mg vs. glimepiride 
4 mg). cOnclusiOns: Liraglutide appears to be a cost-effective adjunct treatment 
for type II diabetes and may also be associated with a reduction in diabetes-related 
complication costs; however, ICER values are largely dependent on the duration of 
liraglutide treatment benefit and the time horizon of the analysis.
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performed to assess the association between CKD stages and HRU/costs. Results: 
The study identified 23,492 T2DM patients (mean age: 60.7 years; no CKD: 54.9%; 
stage 1: 7.1%; stage 2: 12.7%; stage 3A: 15.9%; stage 3B: 7.5%; stage 4: 1.8%). Patients 
with more advanced CKD stages were associated with greater odds of hospitaliza-
tion compared to those without CKD (odds ratio [95% confidence interval] (stage 
1: 1.14 [1.00−1.30]; stage 3A: 1.57 [1.43−1.72]; stage 3B: 1.84 [1.63−2.07]; stage 4: 2.66 
[2.16−3.28]) and ER visits (stage 3A: 1.25 [1.15−1.37]; stage 3B: 1.34 [1.19−1.51]; stage 
4: 1.55 [1.25−1.92]). Patients with CKD stage 1, 2, 3A, 3B, and 4 had total costs of 1.18, 
1.17, 1.44, 1.54, and 1.80 times of those without CKD (all p< 0.01). cOnclusiOns: 
CKD in T2DM patients was associated with higher HRU and costs compared to those 
without CKD. Additionally, HRU and costs increased with more advanced stages 
of CKD. Prevention of CKD progression may help contain the economic burden.
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Objectives: To assess the impact of diabetes on direct medical expenditures 
for visits and prescribed medications related to skin and soft tissue infections 
(SSTIs). MethOds: Hospital inpatient, outpatient, office, and emergency room vis-
its and prescribed medications related to SSTIs were identified from the 2010 and 
2011 Medical Expenditure Panel Survey. Total SSTI costs per patient per year were 
calculated by summing overall costs of all SSTI medical events. Differences in mean 
and median SSTI costs between patients with and without diabetes were assessed 
with the Wilcoxon-Mann-Whitney and median two-sample tests. Results: We 
identified 1684 SSTI events from 438 patients, including 93 (21%) having diabetes. 
Events (761 to 923) and costs ($259,784.74 to $375,696.03) increased from 2010 to 2011. 
Patients with diabetes were older (61 vs. 47) and a greater percentage had public 
insurance (46% vs. 28%). Average SSTI costs per patient with diabetes in 2010 and 
2011 were: $135.84 (standard deviation [sd]= 259.72) and $873.59 (sd= 2275.98) for 
prescribed medicines, $8990.54 (sd= 9506.02) and $8590.86 (sd= 8685.70) for inpatient 
and emergency room, $706.61 (sd= 1729.25) and $1255.25 (sd= 3561.37) for outpa-
tient and office. Average SSTI costs per patient without diabetes in 2010 and 2011 
were: $143.91 (standard deviation [sd]= 411.68) and $46.71 (sd= 78.07) for prescribed 
medicines, $832.92 (sd= 1482.56) and $2431.65 (sd= 7758.02) for inpatient and emer-
gency room, $486.55 (sd= 1237.81) and $568.32 (sd= 1247.08) for outpatient and office. 
The mean total SSTI cost difference between patients with and without diabetes 
was $1627.93 ($2481.09-$853.16, p-value= 0.1441) in 2010 and $1065.60 ($2604.75-
$1539.15, p-value= 0.1789) in 2011. The median total SSTI cost difference per patient 
per year was $78.61 ($237.72-$159.11, p-value= 0.3948) and $38.21 ($237.00-$198.79, 
p-value= 0.2666). cOnclusiOns: In a nationally representative sample, mean and 
median SSTI costs related to medical visits and prescriptions were higher among 
patients with diabetes, however these costs did not differ significantly compared 
to patients without diabetes.
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Objectives: Identify, categorize the two year costs (insurer paid amount) of inten-
sive insulin treatment for patients diagnosed with type 2 diabetes. Focus on inten-
sively-treated patients receiving MDI (multiple daily injections of insulin) or CSII 
(continuous subcutaneous insulin infusion). Investigate and measure the spending 
by payers for these patients determine which related diagnosis contribute the most 
to the two year aggregate. MethOds: Patients and their expenditures were identi-
fied retrospectively using administrative health care insurance claims from the 
2010 and 2011 edition of Truven MarketScan Commercial. Patients were identified 
as having type 2 diabetes based on diagnosis from these claims. Treatment groups 
were assigned from medical-surgical and drug benefit claims for insulin, an insulin 
pump or related supplies. Patients with a claim for type 1 diabetes, gestational dia-
betes, cancer, HIV/AIDS, trauma, organ transplants were excluded. Patients in the 
lowest or highest 99th cost percentile and patients without continuous enrollment 
for the entire period were excluded. Expenditures were segmented by benefit type 
and were stratified separately as “diabetes-related” if the claim’s primary ICD-9-CM 
code was related to diabetes. Conversely, claims with primary diagnosis codes not 
related to diabetes were classified as “not related to diabetes”. Results: After exclu-
sions, there were 20,355 patients identified as MDI and 481 patients identified as 
using CSII. For both groups, the majority of the total treatment expenditures were 
not related to diabetes. For patients in the same treatment cohort of the prior year 
(ie. 2011 vs. 2010), the proportion of expenditures were similar. cOnclusiOns: 
For patients identified as MDI or CSII, non-diabetes related costs were the highest 
contributors to aggregate payer spending. Further analysis is needed to determine 
if other characteristics of the patients analyzed have an effect on the proportion 
of costs.
PDB44
cHarges anD HealtH care resource use in Patients witH tyPe 2 
DiaBetes melitus after treatment initiation witH saxagliPtin or 
sitagliPtin
Sheehan J.1, Moorthy V.2, Colilla S.3, Kalsekar I.1
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Mu Sigma Inc., Hopewell, NJ, USA, 3Bristol-Myers 
Squibb, Hopewell, NJ, USA
Objectives: To compare charges and resource use during the 6 months follow-
ing treatment initiation with saxagliptin or sitagliptin. MethOds: A retrospective 
cohort study using a US insurance claims dataset was conducted to meet the study 
